Restless Legs Syndrome: A Nutrition and Natural-Health Reference
1. Definition and Clinical Presentation
Restless legs syndrome (RLS), or Willis-Ekbom disease, is a common, chronic, multifactorial movement disorder of the limbs in which patients have an irresistible urge to move their legs. It is simultaneously classified as a neurological condition and a sleep disorder, triggered by resting and attempting to sleep.
This condition was first described in 1685 by Sir Thomas Willis, a British anatomist and physician, but it was in 1944 that Karl Axel Ekbom, a Swedish physician, reported all the clinical features and coined the term RLS.
The disorder is defined by four essential diagnostic criteria, as outlined in the International RLS Study Group (IRLSSG) consensus and adopted by the National Institutes of Health:
- An urge to move the legs, usually but not always accompanied by or felt to be caused by uncomfortable and unpleasant sensations in the legs;
- The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting;
- The urge to move the legs and any accompanying unpleasant sensations are partially or fully relieved by movement, such as walking or stretching, at least as long as the activity continues;
- The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.
The sensations may feel like aching, throbbing, pulling, itching, crawling, or creeping. They less commonly affect the arms, rarely occur in the chest or head, and most often affect both sides of the body but can also affect only one side. The uncomfortable feelings are sometimes described by patients as "creeping, crawling, tingling, pulling, or painful" deep inside the limbs, unilaterally or bilaterally occurring with the knees, the ankles, or even the whole lower limbs.
There is an association with involuntary jerking movements of the legs during sleep, known as periodic leg movements of sleep (PLMS). People with RLS have impaired sleep, often associated with periodic limb movements, and increased risk of depression and anxiety, all of which combine to reduce quality of life.
2. Epidemiology and Prevalence
Restless legs syndrome is one of the most common sleep and movement disorders. It affects an estimated 5 to 10 percent of adults and 2 to 4 percent of children in the United States. For unknown reasons, the disorder affects women more often than men, and prevalence increases with age.
The overall global prevalence of RLS is estimated at about 7%, with 2.7% of the population having clinically significant RLS. It remains a common but still underdiagnosed neurologic disorder. Approximately 1 in 4 RLS sufferers is aware of their diagnosis, and overall, 1 in 5 RLS sufferers desire drug treatment to relieve symptoms effectively.
3. Body Systems Involved
Current understanding of the pathophysiology of RLS points to the involvement of three interrelated components: dopaminergic dysfunction, impaired iron homeostasis, and genetic mechanisms.
The Central Nervous System and Dopaminergic Pathways
RLS is a sensorimotor disorder that is frequently associated with periodic leg movements (PLMS). It is generally considered to be a central nervous system (CNS)-related disorder, although no specific lesion has been found to be associated with the syndrome.
Human neuropathologic and imaging studies have consistently shown decreased iron in different brain regions including the substantia nigra and thalamus. These same areas also demonstrate a state of relative dopamine excess. Neuroimaging studies, analysis of cerebrospinal fluid, and studies on postmortem tissue have indicated that low brain iron concentrations and dysfunction of iron metabolism may play key roles in the pathogenesis of RLS. The "iron-dopamine model" explains that iron deficiency in the brain causes an abnormality in the dopaminergic system leading to the manifestation of RLS.
Iron is an important co-factor in dopamine biosynthesis and is intricately involved in the regulation of dopamine levels in the brain. Iron also acts as a co-factor in the regulation of the hypoxia inducible factor (HIF) pathway, and iron deficiency inhibits hydroxylation of HIF-1α by prolyl hydroxylase, leading to stabilization of HIF-1α and activation of the HIF pathway.
Deficits of sensorimotor integration with periodic limb movements during sleep (PLMS) and hyperarousal and sleep disturbances in RLS constitute two pathophysiologically distinct but interrelated clinical phenomena, which appear to depend mostly on alterations in dopaminergic and glutamatergic neurotransmission, respectively.
Circadian Rhythm Systems
RLS symptoms show a significant circadian rhythm and a close relationship to periodic limb movements (PLMs) in clinical observations, while the pathophysiological pathways are still unknown. These symptoms reflect a circadian fluctuation of dopamine in the substantia nigra.
Genetic Architecture
The pathophysiology of this disorder offers an interesting example of interaction between genetics and the environment, considering strong iron metabolism involvement and its interaction with recognized individual genetic factors. Familial aggregation and twin studies estimate its heritability to be approximately 70%, suggesting a major genetic predisposition to RLS.
Genome-wide association studies have identified and replicated 13 new risk loci for restless legs syndrome, confirming six previously identified loci. MEIS1 was confirmed as the strongest genetic risk factor for restless legs syndrome (odds ratio 1.92, 95% CI 1.85–1.99). Gene prioritisation, enrichment, and genetic correlation analyses showed that identified pathways were related to neurodevelopment and highlighted genes linked to axon guidance (associated with SEMA6D), synapse formation (NTNG1), and neuronal specification (HOXB cluster family and MYT1).
Genome-wide association studies have identified 22 genetic risk loci (23 independent variants) associated with RLS, yet only about 12% of the heritability is explained, meaning that much remains to be uncovered.
4. Primary vs. Secondary RLS and Associated Conditions
RLS may occur as an idiopathic, often hereditary condition (primary RLS), or in association with medical conditions (secondary RLS) including iron deficiency, uremia, and polyneuropathy.
The most common causes of secondary RLS are iron deficiency anemia, uremia (renal disease patients), and pregnancy. Following a systematic literature search of RLS associated with comorbidities, one systematic review identified an increased prevalence of RLS only in iron deficiency and kidney disease with strong methodological support. In cardiovascular disease, arterial hypertension, diabetes, migraine, and Parkinson disease, the methodology of studies was poor, but an association may be possible.
Several other disorders increase the risk of developing the condition, including end-stage renal disease, diabetes mellitus, multiple sclerosis, rheumatoid arthritis, and Parkinson's disease.
Pregnancy
The prevalence of RLS during pregnancy is two to three times higher than in the normal population and is influenced by the trimester and the number of parity. The main mechanisms that may contribute to the pathophysiology of RLS during pregnancy are hormonal changes and iron and folate status. In one longitudinal study, the prevalence of RLS increased from 0 during preconception to 23% during the third trimester of pregnancy, and only 1 subject continued to experience RLS after delivery.
Renal Disease
RLS affects 6.6% to 62% of patients on long-term dialysis therapy and is associated with a greater mortality risk. Limited studies of patients with uremic RLS suggest that anemia, hyperphosphatemia, and psychological factors may also have a role. Symptoms of uremic RLS will disappear within a few weeks of successful renal transplantation.
Attention Deficit Hyperactivity Disorder (ADHD)
Pregnant women, patients with end-stage renal disease or iron-deficiency anemia, and children with attention deficit hyperactivity disorder (AD/HD) have a significantly higher prevalence of RLS.
5. Nutrients Studied in Relation to RLS
A 2024 systematic review examined the potential of dietary supplements to manage RLS symptoms and reduce reliance on medications, analyzing a total of 10 randomized clinical trials involving 482 participants, focusing on the impact of various supplements on symptom severity, sleep quality, and daytime sleepiness. Despite some encouraging results, a high risk of bias was noted in half of the studies, emphasizing the need for more rigorous research.
Iron
Pathophysiological Role: Neuroimaging, analysis of cerebrospinal fluid, and studies on postmortem tissue are generating data that support the concept that iron availability to the brain is a contributory process to, if not a cause of, restless legs syndrome. Iron, as a cofactor in dopamine production, plays a central role in the etiology of RLS.
Clinical Evidence: MRI and autopsy studies have demonstrated that brain iron status is insufficient in individuals with RLS. The concept of deficient brain iron status is supported by proteomic studies from cerebrospinal fluid and from clinical findings where intervention with iron, either dietary or intravenous, can improve RLS symptoms.
Oral iron has promising results in RLS, indicating potential efficacy but with issues related to compliance and absorption. The International Restless Legs Syndrome Study Group clinical guidelines and consensus recommend that oral iron therapy should only be considered for adults with RLS whose serum ferritin levels are less than 75 micrograms per liter.
Magnesium
Proposed Mechanism: Magnesium is involved in neuronal excitability regulation. Clinical workups for RLS include assessment of magnesium levels alongside other nutrients such as vitamin B-12, thyroid-stimulating hormone, and folate.
Scientific Evidence: In the 2024 systematic review of 10 RCTs, magnesium oxide and vitamin B6 significantly improved sleep quality and RLS symptoms, with magnesium showing greater effectiveness. A separate 2025 systematic review and meta-analysis confirmed that vitamin B6 significantly reduced RLS patients' International RLS (IRLS) scores and Pittsburgh Sleep Quality Index (PSQI) scores compared to placebo, and was comparable to magnesium oxide. However, the overall evidence base for magnesium in RLS remains limited by small sample sizes and mixed study quality, and results should be interpreted cautiously.
Vitamin B6 (Pyridoxine)
Scientific Evidence: Clinical trial data indicate that vitamin B6 significantly reduced RLS patients' IRLS scores and PSQI scores compared to placebo, and was found to be comparable in effect to magnesium oxide. The proposed mechanism relates to B6's role as a cofactor in neurotransmitter synthesis, including dopamine. Evidence is currently limited to small RCTs, and larger trials are needed to confirm these findings.
Folate (Vitamin B9)
Traditional and Observational Context: Folate has historically been associated with RLS in the context of pregnancy and specific secondary forms of the disorder.
Scientific Evidence: In one longitudinal study of pregnant women, those with restless legs had low serum ferritin at preconception and significantly lower folate levels during preconception and at each trimester. Rather than indicators of iron deficiency anemia (serum ferritin, serum iron, and hemoglobin) or pernicious anemia (vitamin B12), it was reduced serum folate level that was associated with RLS in this sample of pregnant women.
A 2025 meta-analysis found that low folate levels were associated with RLS only in pregnant women, suggesting that the folate-RLS relationship may be specific to pregnancy-related secondary RLS rather than primary idiopathic RLS. Evidence overall is observational and limited.
Vitamins C and E
Scientific Evidence: Oral vitamin C could significantly reduce IRLS scores in hemodialysis-associated RLS patients compared to placebo, and was comparable to pramipexole (a standard dopamine agonist). Oral vitamin E could significantly reduce IRLS scores in hemodialysis-associated RLS patients compared to placebo, and was equivalent in effect to vitamin C. Both vitamins C and E positively affect RLS symptoms in these populations, likely due to their antioxidant properties.
Importantly, these findings come exclusively from the hemodialysis/uremic RLS population, where oxidative stress is elevated. Evidence in primary (idiopathic) RLS is absent, making generalization to the broader RLS population premature.
Vitamin D
Observational Data: A 2025 meta-analysis found low vitamin D levels in patients with RLS, suggesting a possible association. However, the direction of causality is unclear.
Intervention Evidence: Vitamin D supplementation did not show significant benefits in clinical trials for RLS outcomes. Vitamin D did not reduce patients' RLS severity score compared to placebo, regardless of vitamin D deficiency status. At present, the evidence does not support vitamin D supplementation as an effective intervention for RLS symptom reduction, despite the observed association with lower levels.
Vitamin B12
Vitamin B-12 is included among the nutrients assessed in the clinical workup of RLS, given its role in nervous system function. Among the 57 papers in one systematic review that focused on the relationship between vitamins and RLS, 24 studies examined vitamin B12. However, robust clinical trial evidence specifically linking B12 supplementation to RLS symptom improvement is currently lacking, and its inclusion in workups is primarily to rule out deficiency states that could contribute to neurological symptoms.
6. Herbs and Natural Ingredients
Valerian (Valeriana officinalis)
Traditional Use: Valerian root has a long history of use in European herbal medicine as a sedative and sleep-promoting agent, dating back to ancient Greece and Rome. It was employed across Western herbal traditions, particularly in 18th- and 19th-century German and British herbalism, primarily as a nervine and antispasmodic for anxiety, insomnia, and restlessness. Preparations typically involved dried root tinctures or decoctions.
Scientific Evidence: A prospective, triple-blinded, randomized, placebo-controlled, parallel-design trial compared the effects of 800 mg of valerian with a placebo on sleep quality and symptom severity in people with RLS, with 37 participants randomly assigned to receive valerian or placebo for 8 weeks. Both groups reported improvement in RLS symptom severity and sleep. In the 2024 systematic review, valerian improved RLS and sleep but did not show a statistically significant improvement over placebo.
In a crossover clinical trial comparing valerian and gabapentin in 40 hemodialysis patients, the mean score of RLS was lower in the gabapentin group after the first phase, but there was no statistically significant difference between the two groups in terms of sleep quality. Gabapentin was found to be more effective than valerian in improving RLS, but both were equally effective in improving sleep quality.
Overall, the scientific evidence for valerian in RLS is preliminary. Studies are small, and most have not demonstrated statistically significant superiority over placebo for core RLS symptoms. Larger, well-controlled trials are needed.
7. Dietary and Lifestyle Factors
Overall Lifestyle Pattern and RLS Risk
In a large prospective cohort study identifying 1,538 incident RLS cases over 4–6 years of follow-up, participants with normal weight who were physically active, non-smokers, and had some alcohol consumption had a lower risk of developing RLS. When the effects of these four factors were combined, a dose-response relationship was observed between an increased number of healthy lifestyle factors and low risk of RLS: after adjusting for potential confounders, the pooled odds ratio was 0.67 (95% CI: 0.47–0.97) for 4 vs. 0 healthy factors (p trend < 0.001).
Body Weight
Participants with normal weight had a lower risk of developing RLS in prospective cohort data. The association between obesity and RLS risk has been noted in several population-based studies, although the causal pathway remains incompletely understood.
Caffeine
In the prospective cohort study, no significant associations were observed between caffeine consumption and altered RLS risk in men and women. Nevertheless, clinical guidance from authoritative sources frequently cites caffeine as a potential exacerbating factor, particularly when consumed close to bedtime, given its ability to disrupt sleep architecture generally. The evidence base specifically linking caffeine to RLS worsening or onset remains largely empirical rather than from controlled trials.
Alcohol
The relationship between alcohol and RLS is complex and context-dependent. The large prospective cohort found that some alcohol consumption was associated with a lower risk of developing RLS compared to complete abstinence. However, this reflects population-level epidemiological data from a multi-factor analysis and does not address acute effects; clinical experience and sleep medicine guidance consistently note that alcohol can acutely disrupt sleep architecture and may worsen RLS symptoms on an episode-by-episode basis in some individuals.
Physical Activity and Exercise
In one early randomized controlled trial involving 28 participants (average age 53.7; 39% males) over a 12-week trial, the exercise group was prescribed a conditioning program of aerobic and lower-body resistance training 3 days per week.
Both aerobic exercise and stretching exercise programs performed 3 times a week for 8 weeks reduced RLS symptoms and improved quality of life in patients with primary RLS in a controlled study examining different exercise modalities.
A yoga-based approach has also been evaluated: an exploratory randomized controlled trial assessed the effects of a yoga versus educational film (EF) program on RLS symptoms and related outcomes in 41 community-dwelling, ambulatory non-pregnant adults with moderate to severe RLS randomized to a 12-week yoga or EF program. The exercise and yoga literature for RLS shows consistent signals of benefit, but individual studies are generally small and exploratory, requiring confirmation by larger trials.
Dietary Iron Intake
Given the well-established role of iron in RLS pathophysiology, dietary iron intake is a frequently discussed factor. The concept of deficient brain iron status is supported by clinical findings where intervention with iron, either dietary or intravenous, can improve RLS symptoms. Dietary sources rich in bioavailable iron — such as red meat, organ meats, legumes, and leafy greens — are implicated by extension, though specific dietary pattern trials for RLS are limited.
Gluten and Celiac Disease
An emerging area of interest is the relationship between celiac disease, gluten intolerance, and RLS. A 2023 systematic review linked celiac disease and gluten intolerance to RLS. The proposed mechanism may relate to the malabsorption of iron and folate that accompanies untreated celiac disease, rather than any direct neurological effect of gluten. Evidence in this area is early and primarily observational.
Medications That Exacerbate RLS
Several commonly used substances and medications have been identified as potentially worsening RLS. Clinical evidence suggests that treatment should involve the reduction of potential exacerbating agents including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), lithium, and dopamine antagonists. Antihistamines and certain anti-nausea drugs acting as dopamine antagonists are also noted in clinical literature as capable of exacerbating RLS, though these are pharmaceutical rather than dietary considerations.
8. Summary of Evidence Strength
- Iron (brain iron deficiency and iron supplementation): Strong mechanistic evidence from neuroimaging, cerebrospinal fluid, and postmortem studies; moderate clinical evidence for supplementation in iron-deficient populations; evidence is most robust for secondary RLS associated with iron deficiency anemia and renal disease.
- Magnesium and Vitamin B6: Preliminary positive evidence from small RCTs; statistically significant improvements noted in the 2024 systematic review of 10 trials (482 participants), but high risk of bias limits conclusions.
- Vitamins C and E: Preliminary evidence from hemodialysis/uremic RLS populations only; not generalizable to primary RLS without further study.
- Folate: Weak and population-specific evidence; association with RLS confirmed primarily in pregnant women; not demonstrated in primary RLS populations.
- Vitamin D: Observational association with lower levels in RLS patients, but supplementation trials have not demonstrated significant benefit on RLS severity.
- Valerian: Weak and preliminary evidence; small trials show some sleep benefit but no statistically significant superiority over placebo for RLS-specific outcomes.
- Exercise and physical activity: Consistent signals of benefit across multiple small RCTs; aerobic, resistance, stretching, and yoga formats have all been studied with positive directional findings; evidence is preliminary due to small sample sizes.
- Caffeine restriction: Evidence is empirical; not supported by prospective cohort data on RLS incidence risk, though sleep disruption effects are well established generally.
References
Go back